Relapsing Polychondritis

Sosada, Beata; Loza, Kateryna; Biało-Wójcicka, Ewelina

doi:10.1155/2014/791951

Cited by 15 publications

(21 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mild manifestations can be also managed with dapsone (50–100 mg, once daily; maximum dose of 200 mg, once daily) or colchicine (0.6 mg 2–4 times daily) [ 82 , 83 , 84 ]. In the case of NSAIDs resistance or in severe forms including ocular, laryngotracheal, or cardiac involvement, systemic vasculitis and severe polychondritis, systemic corticosteroids are considered the treatment of choice [ 85 , 86 ]. Oral prednisone is usually started with a dose ranging from 0.25 to 1 mg/kg daily, reducing the dose, if possible, during the course of the disease [ 80 , 86 ].…”

Section: Therapymentioning

confidence: 99%

Relapsing Polychondritis: An Updated Review

et al. 2018

View full text Add to dashboard Cite

Relapsing polychondritis is an immune-mediated systemic disease characterized by recurrent episodes of inflammation of cartilaginous and proteoglycan-rich tissues, resulting in progressive anatomical deformation and functional impairment of the involved structures. Auricular and nasal chondritis and/or polyarthritis represent the most common clinical features, but potentially all types of cartilage may be involved. Because of the pleomorphic nature of the disease, with non-specific symptoms at the onset, the diagnosis of relapsing polychondritis is often delayed. In this review article we provide a comprehensive look into clinical presentation, laboratory and instrumental investigations, diagnostic criteria, and therapeutic options.

show abstract

Section: Therapymentioning

confidence: 99%

Relapsing Polychondritis: An Updated Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The second treatment option for this serious disease, or in patients which are intolerant to corticosteroids, those who become addicted to corticosteroids or have a lack of response to corticosteroids, consisted of other classes of pharmaceutical compounds. For example, drugs such as Cyclophosphamide, Azathioprine, Cyclosporine or Methotrexate (alone or in association with systemic corticosteroids) were used in the pharmaceutical protocols [25][26][27][28][29]. Other proposed treatments included the following drugs: 6-mercaptopurine, plasmapheresis, anti-CD4 monoclonal antibody, penicillamine, minocycline, high-dose intravenous immunoglobulins, leinflamide [24,[30][31][32][33][34].…”

Section: Resultsmentioning

confidence: 99%

Importance of Chemical Therapy in Relapsing Polychondritis � a Disease with Impact on the Eye Tissues

Jurja¹,

Mehedinți²,

Sîrbu³

et al. 2020

Rev. Chim.

View full text Add to dashboard Cite

Relapsing polychondritis (RP), falls into the category of rare diseases. The true incidence and prevalence of this rare disease is unknown. The ocular implications in relapsing polychondritis (RP) are numerous and variable, including mainly inflammation in different structures of the eye. As a complication of this inflammatory condition, a closed secondary angle glaucoma has been described. The purpose of our work is to highlight the diversity of ocular determinations of the same rare disease, including different types of glaucoma that may occur under the same circumstances and to make a detailed analysis of chemical therapies based on drug treatment pathways. The paper includes a report of the cases series admitted to the Clinic of Ophthalmology in St. Andrew Emergency Clinical Hospital, Constanta, between 2007 and 2018, cases analyzed and compared with international literature. One of the cases is a 43-year-old male patient with bilateral open-angle bilateral glaucoma. Other cases with RP, are patients of 41 and 46 years old, respectively, presented with unilateral episcleritis. This case series report aims to show that RP can associate even more protean ocular manifestations than already discussed in the literature, with specific chemical therapies and to emphasize the need for team approach and ophthalmological monitoring in the care of RP patients with chemical therapy (drug treatment) for each patient.

show abstract

“…There are few available criterias to diagnose RP [ 3 ]. The McAdam's criteria were the initial diagnostic criteria of RP and required three out of six criterias of the following: bilateral auricular chondritis, nonerosive seronegative inflammatory arthritis, nasal chondritis, ocular inflammation, respiratory tract chondritis, and audiovestibular damage [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Multiple endobronchial airway stents in a case of relapsing polychondritis - A rare entity

Alaga

Mohammed

Ishida

et al. 2022

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Relapsing polychondritis (RP) is a rare multisystem condition. Nearly 50% of patients are suffering from airway involvement in RP and it can be fatal. Besides immunotherapies, endobronchial stenting has been found to be useful in the treatment. Insertion of endobronchial stents in patients with RP has it’s own complications and has been associated with increasing morbidity and mortality. We describe placement of multiple endobronchial stents to prevent airway closure in a 76-year-old man with RP due to recurrent dyspnea. Insertion of multiple stents (6th stent) in the left main bronchus was necessary due to severe narrowing of the left main bronchus. Recurrence of airway involvement in RP is common. Early diagnosis and prompt treatment are essential to reduce the risk of life-threatening airway collapse. The insertion of multiple stents in this patient has resulted in improving symptoms, spirometry, and a return to daily activities.

show abstract

Relapsing Polychondritis

Cited by 15 publications

References 13 publications

Relapsing Polychondritis: An Updated Review

Relapsing Polychondritis: An Updated Review

Importance of Chemical Therapy in Relapsing Polychondritis � a Disease with Impact on the Eye Tissues

Multiple endobronchial airway stents in a case of relapsing polychondritis - A rare entity

Contact Info

Product

Resources

About